Should anxiety and insomnia influence antidepressant selection: A andomized comparison of fluoxetine and imipramine

Journal of Clinical Psychiatry

Volumn 59, Issue 2, 1998, Pages 49-55

  Simon, Gregory E ^a,c,e   Heiligenstein, John H ^b   Grothaus, Louis ^a   Katon, Wayne ^c   Revicki, Dennis ^d  

^a CENTER FOR HEALTH STUDIES   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNITED BIOSOURCE CORPORATION   (United States)

^e CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; TRAZODONE;

ADULT; AGED; AGITATION; ANXIETY; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DYSTHYMIA; FEMALE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION;

EID: 0031914091     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v59n0202     Document Type: Article

References (21)

1. Song F, Freemantle N, Sheldon T, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993;306: 683-687
2. Workman EA, Short DD. Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. J Clin Psychiatry 1993;54:5-12
3. Simon G, VonKorff M, Wagner EH, et al. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993;15:399-408
4. Agency for Health Care Policy and Research. Clinical Practice Guideline, No. 5: Depression in Primary Care, vol 2, Treatment of Major Depression. AHCPR publication 93-0551. Rockville, Md: US Dept Health and Human Services; April 1993
5. Choice of an antidepressant. Med Lett Drugs Ther 1993;35:25-26
6. Matthews J, Eagles JM. Which antidepressant? Br J Gen Pract 1991;41: 123-125
7. Tyrer P, Lee I, Edwards JG, et al. Prognostic factors determining response to antidepressant drugs in psychiatric out-patients and general practice. J Affect Disord 1980;2:149-156
8. Joyce P, Paykel ES. Predictors of drug response in depression. Arch Gen Psychiatry 1989;46:89-99
9. Tollefson GD, Holman SL, Sayler ME, et al. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry 1994;55:50-59
10. Tollefson G, Greist JH, Jefferson JW, et al. Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: a comparative trial of fluoxetine versus imipramine. J Clin Psychopharmacol 1994;14: 385-391
11. Beasley CM Jr, Domseif BE, Pultz JA, et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry 1991;52: 294-299
12. Katon W, VonKorff M, Lin E, et al. Collaborative management to achieve treatment guidelines: impact on depression in primary care. JAMA 1995; 273:1026-1031
13. Lin E, VonKorff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995;33:67-74
14. Simon G, Wagner E, VonKorff M. Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs. J Clin Epidemiol 1995;48:363-373
15. Simon G, VonKorff M, Heiligenstein JH, et al. Initial antidepressant selection in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996;275:1897-1902
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
17. Williams JBW. A Structured Interview Guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 1988;45:742-747
18. Simon G, VonKorff M, Revicki D. Telephone assessment of depression severity. J Psychiatr Res 1993;27(3):247-252
19. Derogatis LR, Lipman RS, Rickels K, et al. The Hopkins Symptom Checklist: a measure of primary symptom dimensions. In: Pichot P, ed. Psychological Measurement: Modern Problems in Pharmacopsychiatry, vol 7. New York, NY: Karger; 1974:79-110
20. Sackett D, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med 1979;301:1410-1412
21. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222